Inactivated Viral Vaccine BBV87 Protects Against Chikungunya Virus Challenge in a Non-Human Primate Model
Chikungunya virus (CHIKV) is an alphavirus transmitted by mosquitos that poses a threat to global public health and for which there is an urgent need for widespread access to globally licensed vaccines. Here, we demonstrate that an inactivated CHIKV vaccine (BBV87) protects against systemic infectio...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/17/4/550 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850180374070558720 |
|---|---|
| author | Sarah L. Kempster Deborah Ferguson Claire Ham Joanna Hall Adrian Jenkins Elaine Giles Simon L. Priestnall Alejandro Suarez-Bonnet Pierre Roques Roger Le Grand Sumathy Kandaswamy Sushant Sahastrabuddhe Libia Milena Hernandez Sunee Chuasuwan Hyeon Seon Ahn Deok Ryun Kim Anh Wartel Raphaël M. Zellweger Neil Berry Neil Almond |
| author_facet | Sarah L. Kempster Deborah Ferguson Claire Ham Joanna Hall Adrian Jenkins Elaine Giles Simon L. Priestnall Alejandro Suarez-Bonnet Pierre Roques Roger Le Grand Sumathy Kandaswamy Sushant Sahastrabuddhe Libia Milena Hernandez Sunee Chuasuwan Hyeon Seon Ahn Deok Ryun Kim Anh Wartel Raphaël M. Zellweger Neil Berry Neil Almond |
| author_sort | Sarah L. Kempster |
| collection | DOAJ |
| description | Chikungunya virus (CHIKV) is an alphavirus transmitted by mosquitos that poses a threat to global public health and for which there is an urgent need for widespread access to globally licensed vaccines. Here, we demonstrate that an inactivated CHIKV vaccine (BBV87) protects against systemic infection with CHIKV in a non-human primate (NHP) challenge model. Groups of five cynomolgus macaques received two doses of 20 µg BBV87 vaccine or saline alone (28 days apart). Twenty-eight days after the second immunisation, all animals were challenged with CHIKV. All controls were productively infected with detectable viremia and pathological responses following challenge, including altered thermoregulation, haematological and cytokine changes. Critically, the histopathological analysis of finger joints identified areas of inflammation in the synovium. By contrast vaccinated macaques had no detectable viremia and none of the pathological changes were reported in control animals. This study demonstrates that a 20 µg dose of BBV87 vaccine confers robust protection in vivo, both on the acquisition of infection and pathology. |
| format | Article |
| id | doaj-art-4c78d0fc7568447985e7c80ce5cf02f0 |
| institution | OA Journals |
| issn | 1999-4915 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj-art-4c78d0fc7568447985e7c80ce5cf02f02025-08-20T02:18:11ZengMDPI AGViruses1999-49152025-04-0117455010.3390/v17040550Inactivated Viral Vaccine BBV87 Protects Against Chikungunya Virus Challenge in a Non-Human Primate ModelSarah L. Kempster0Deborah Ferguson1Claire Ham2Joanna Hall3Adrian Jenkins4Elaine Giles5Simon L. Priestnall6Alejandro Suarez-Bonnet7Pierre Roques8Roger Le Grand9Sumathy Kandaswamy10Sushant Sahastrabuddhe11Libia Milena Hernandez12Sunee Chuasuwan13Hyeon Seon Ahn14Deok Ryun Kim15Anh Wartel16Raphaël M. Zellweger17Neil Berry18Neil Almond19Science and Research, Diagnostics, Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms EN6 3QG, Hertfordshire, UKScience and Research, Diagnostics, Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms EN6 3QG, Hertfordshire, UKScience and Research, Diagnostics, Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms EN6 3QG, Hertfordshire, UKScience and Research, Diagnostics, Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms EN6 3QG, Hertfordshire, UKScience and Research, Diagnostics, Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms EN6 3QG, Hertfordshire, UKScience and Research, Diagnostics, Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms EN6 3QG, Hertfordshire, UKDepartment Pathobiology & Population Sciences, The Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield AL9 7TA, Hertfordshire, UKDepartment Pathobiology & Population Sciences, The Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield AL9 7TA, Hertfordshire, UKINSERM, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, 92260 Fontenay-aux-Roses, FranceINSERM, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, 92260 Fontenay-aux-Roses, FranceBharat Biotech International Ltd., Hyderabad 500078, IndiaInternational Vaccine Institute (IVI), Seoul 08800, Republic of KoreaInternational Vaccine Institute (IVI), Seoul 08800, Republic of KoreaInternational Vaccine Institute (IVI), Seoul 08800, Republic of KoreaInternational Vaccine Institute (IVI), Seoul 08800, Republic of KoreaInternational Vaccine Institute (IVI), Seoul 08800, Republic of KoreaInternational Vaccine Institute (IVI), Seoul 08800, Republic of KoreaInternational Vaccine Institute (IVI), Seoul 08800, Republic of KoreaScience and Research, Diagnostics, Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms EN6 3QG, Hertfordshire, UKScience and Research, Diagnostics, Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms EN6 3QG, Hertfordshire, UKChikungunya virus (CHIKV) is an alphavirus transmitted by mosquitos that poses a threat to global public health and for which there is an urgent need for widespread access to globally licensed vaccines. Here, we demonstrate that an inactivated CHIKV vaccine (BBV87) protects against systemic infection with CHIKV in a non-human primate (NHP) challenge model. Groups of five cynomolgus macaques received two doses of 20 µg BBV87 vaccine or saline alone (28 days apart). Twenty-eight days after the second immunisation, all animals were challenged with CHIKV. All controls were productively infected with detectable viremia and pathological responses following challenge, including altered thermoregulation, haematological and cytokine changes. Critically, the histopathological analysis of finger joints identified areas of inflammation in the synovium. By contrast vaccinated macaques had no detectable viremia and none of the pathological changes were reported in control animals. This study demonstrates that a 20 µg dose of BBV87 vaccine confers robust protection in vivo, both on the acquisition of infection and pathology.https://www.mdpi.com/1999-4915/17/4/550chikungunya virusvaccinenon-human primatepathogenesisimmunity |
| spellingShingle | Sarah L. Kempster Deborah Ferguson Claire Ham Joanna Hall Adrian Jenkins Elaine Giles Simon L. Priestnall Alejandro Suarez-Bonnet Pierre Roques Roger Le Grand Sumathy Kandaswamy Sushant Sahastrabuddhe Libia Milena Hernandez Sunee Chuasuwan Hyeon Seon Ahn Deok Ryun Kim Anh Wartel Raphaël M. Zellweger Neil Berry Neil Almond Inactivated Viral Vaccine BBV87 Protects Against Chikungunya Virus Challenge in a Non-Human Primate Model Viruses chikungunya virus vaccine non-human primate pathogenesis immunity |
| title | Inactivated Viral Vaccine BBV87 Protects Against Chikungunya Virus Challenge in a Non-Human Primate Model |
| title_full | Inactivated Viral Vaccine BBV87 Protects Against Chikungunya Virus Challenge in a Non-Human Primate Model |
| title_fullStr | Inactivated Viral Vaccine BBV87 Protects Against Chikungunya Virus Challenge in a Non-Human Primate Model |
| title_full_unstemmed | Inactivated Viral Vaccine BBV87 Protects Against Chikungunya Virus Challenge in a Non-Human Primate Model |
| title_short | Inactivated Viral Vaccine BBV87 Protects Against Chikungunya Virus Challenge in a Non-Human Primate Model |
| title_sort | inactivated viral vaccine bbv87 protects against chikungunya virus challenge in a non human primate model |
| topic | chikungunya virus vaccine non-human primate pathogenesis immunity |
| url | https://www.mdpi.com/1999-4915/17/4/550 |
| work_keys_str_mv | AT sarahlkempster inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT deborahferguson inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT claireham inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT joannahall inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT adrianjenkins inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT elainegiles inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT simonlpriestnall inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT alejandrosuarezbonnet inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT pierreroques inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT rogerlegrand inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT sumathykandaswamy inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT sushantsahastrabuddhe inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT libiamilenahernandez inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT suneechuasuwan inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT hyeonseonahn inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT deokryunkim inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT anhwartel inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT raphaelmzellweger inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT neilberry inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel AT neilalmond inactivatedviralvaccinebbv87protectsagainstchikungunyaviruschallengeinanonhumanprimatemodel |